FDA expanding access to pancreatic cancer drug to some patients

The FDA announced it is expanding access to a pancreatic cancer drug that showed nearly doubled survival time for patients with advanced pancreatic cancer in a large clinical trial. This decision aims to provide earlier access to the promising treatment.